12,683 Shares in Frequency Therapeutics, Inc. (NASDAQ:FREQ) Bought by Tortoise Investment Management LLC

Tortoise Investment Management LLC purchased a new position in shares of Frequency Therapeutics, Inc. (NASDAQ:FREQ – Get Rating) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 12,683 shares of the company’s stock, valued at approximately $27,000.

A number of other hedge funds have also bought and sold shares of FREQ. Allspring Global Investments Holdings LLC bought a new stake in Frequency Therapeutics during the first quarter worth $54,000. North Star Investment Management Corp. bought a new stake in shares of Frequency Therapeutics in the first quarter valued at $127,000. Walleye Capital LLC raised its stake in shares of Frequency Therapeutics by 21.8% in the fourth quarter. Walleye Capital LLC now owns 146,208 shares of the company’s stock valued at $750,000 after buying an additional 26,167 shares during the period. GSA Capital Partners LLP raised its stake in shares of Frequency Therapeutics by 169.4% in the fourth quarter. GSA Capital Partners LLP now owns 219,932 shares of the company’s stock valued at $1,128,000 after buying an additional 138,280 shares during the period. Finally, Lombard Odier Asset Management Switzerland SA raised its stake in shares of Frequency Therapeutics by 9.2% in the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 707,071 shares of the company’s stock valued at $3,627,000 after buying an additional 59,806 shares during the period. 50.64% of the stock is currently owned by institutional investors.

Frequency Therapeutics Stock Down 0.9 %

Shares of FREQ opened at $2.23 on Friday. The stock’s fifty day moving average price is $1.63 and its two-hundred day moving average price is $2.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.85 and a current ratio of 9.85. Frequency Therapeutics, Inc. has a 1 year low of $1.00 and a 1 year high of $8.60.

Frequency Therapeutics (NASDAQ:FREQ – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.01). As a group, equities research analysts anticipate that Frequency Therapeutics, Inc. will post -2.51 earnings per share for the current year.

About Frequency Therapeutics

(Get Rating)

Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.